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Summary
We designed a minilibrary of 55 small molecule pepti-
domimetics based on -turns of the neurotrophin
growth factor polypeptides neurotrophin-3 (NT-3) and
nerve growth factor (NGF). Direct binding, binding
competition, and biological screens identified agonis-
tic ligands of the ectodomain of the neurotrophin re-
ceptors TrkC and TrkA. Agonism is intrinsic to the
peptidomimetic ligand (in the absence of neurotroph-
ins), and/or can also be detected as potentiation of
neurotrophin action. Remarkably, some peptidomi-
metics afford both neurotrophic activities of cell sur-
vival and neuronal differentiation, while others afford
discrete signals leading to either survival or differen-
tiation. The high rate of hits identified suggests that
focused minilibraries may be desirable for developing
bioactive ligands of cell surface receptors. Small, se-
lective, proteolytically stable ligands with defined bio-
logical activity may have therapeutic potential.*Correspondence: Uri.Saragovi@mcgill.ca
7 Present address: Department of Chemistry, Faculty of Science,
Chiang Mai University, Chiang Mai 50200, Thailand.Introduction
Neurotrophins are dimeric polypeptide growth factors
that regulate the peripheral and central nervous sys-
tems and other tissues [1, 2]. Neurotrophins and their
receptors are validated targets for therapeutics in a
variety of pathologies, ranging from cancer to neurode-
generation [1, 3–5]. However, therapeutic uses of the
neurotrophins have failed because they cause full re-
ceptor activation, which leads to toxicity and pleio-
trophic effects, short half-lives, and inability to reach
target tissues [6, 7].
Neurotrophic activities arise from ligand binding to
two types of cell surface receptors. The Trk family of
receptors are tyrosine kinases. Ligand binding induces
phosphorylation (pTyr) of TrkA and associated signaling
partners, and activation of the “traditional” neurotrophic
biological signals. These signals promote growth or
survival under stress (trophic activity) and cellular dif-
ferentiation (neuritogenic activity).
The Trk receptors are selective and of high affinity for
neurotrophins (wKd 10−11 M). Nerve growth factor
(NGF) docks with TrkA, neurotrophin-3 (NT-3) interacts
with TrkC, but can also bind TrkA, and brain-derived
neurotrophic factor (BDNF) interacts with TrkB [8]. The
Trk extracellular domain consists of 5 subdomains: the
N-terminal leucine-rich motif (LRM), two cysteine-rich
clusters, and two imunoglobulin (Ig)-like subdomains,
IgC1 and IgC2 (also respectively known as D4 and D5)
[9]. The D5 subdomain is the main site for NGF/TrkA,
BDNF/TrkB, or NT-3/TrkC binding and functionality [10].
The D4 subdomain regulates the levels of receptor au-
tophosphorylation, and its mutagenesis can result in
oncogenic autoactivation [10–13]. The LRM subdomain
is another activation site that mediates NGF/TrkA func-
tionality [10]. These regulatory or activation sites define
functional “hot spots” of the receptors, and are targets
for the development of ligands [14–18] that bind a de-
fined activation or regulatory hot spot (e.g., only the D5
or only the LRM subdomains). We reasoned that li-
gands binding these hot spots could afford partial re-
ceptor activation or regulation, as opposed to full re-
ceptor activation.
The p75 receptor is a member of the tumor necrosis
factor (TNF) receptor superfamily. All the neurotrophins
bind the p75 receptor, but with lesser affinities, varying
from low (10−9 M) to high (10−11 M) [19–21]. Depending
on the cellular environment and the ligand available,
the p75 receptor can transduce signals that are either
prosurvival, proapoptotic, or prodifferentiation [22, 23].
The p75 receptor also regulates Trk function and Trk
ligand docking preference [9, 10]. These features make
p75 biology extremely complex and the behavior of p75
ligands difficult to predict. Consequently, we reasoned
that it would be desirable to develop peptidomimetic
ligands that target Trk receptors and exclude p75.
Previously, we used protein mimicry to develop disul-
fide-linked cyclic peptides that bind TrkA as agonists
or antagonists [24–27]. The peptides adopt β-turn con-
formations similar to regions of the proteins from which
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1016they were designed [28, 29]. One early lead β-turn pep-
tidomimetic ligand, termed D3, is a partial agonist se-
lective for TrkA. D3 is proteolytically stable, it induces
TrkA-TrkA homodimers, potentiates the effect of NGF in
activating the receptor [26], and induces TrkA tyrosine
phosphorylation. However, D3 has low intrinsic agonis-
tic activity at TrkA, and it could be best described as an
NGF potentiator, synergistically enhancing NGF action.
Thus, we sought to design improved agents and ap-
plied the mimicry concepts that evolved from de-
veloping earlier NGF mimetics [30] to the neurotrophin
family member NT-3.
We designed a library of peptidomimetics based on
β-turn NT-3 structure, with the rationale of targeting the
extracellular domain of the TrkC and TrkA receptors,
and perhaps excluding p75. The design also aimed to
enhance the intrinsic agonistic activity of the peptido-
mimetics and to reduce the size and the peptidic char-
acter of the compounds.
The resulting new peptidomimetics are less peptidic
than D3 and express relevant sequences from the
β-turn pharmacophores. Conformational and molecular
dynamic studies have shown that these new peptido-
mimetics adopt the desired β-turn configurations and
are more rigid than D3 [31–33]. Binding and biological
screens lead to the identification of water-soluble,
small molecule (mass w600 Da) agonistic ligands of
TrkC and TrkA receptors. A subset of peptidomimetics
are selective agonists of TrkC, and another subset are
agonists of both TrkC and TrkA. Direct binding assays
using fluorescinated peptidomimetics demonstrated
binding specificity toward Trk receptors. Also, we show
that some peptidomimetics competitively block the
binding of other agonists that bind to the Ig-C2 (D5)
extracellular hot spot of TrkA or TrkC. Interestingly,
some agonistic peptidomimetics can activate both tro-
phic survival and neuritogenic differentiation, and some
can activate only one pathway.
Our findings demonstrate that a small molecule pep-
tidomimetic can selectively bind and activate Trk recep-
tors, and that it is possible to transduce either single or
multiple signal pathways by engaging hot spots of wild-
type receptors. This work may help us understand how
the neurotrophins function via Trk receptors, and may
be a step forward in the search for small, proteolytically
stable molecules with possible therapeutic potential in
cognitive (TrkA) or motor neuron (TrkC) disorders. The
high rate of success of this approach suggests that
similar focused library approaches designed specific-
ally to target receptor hot spots may be useful for iden-
tifying functional ligands.
Results
Design and Synthesis of a D3-like Library
of Ligands for TrkC and TrkA
We prepared three β-turn backbones, coded 1–3 (Fig-
ure 1A), each with four amine substituents X, coded
A–D (Figure 1B), where A = NH2 (amine); B = NH-C(=NH)
NH2 (guanidine); C = NHSO2CH3 (methyl sulfonamide);
and D = NH-Arg, for a total of 12 possible β-turn tem-
plates. In these 12 templates, we incorporated selected
dipeptide sequences, coded a–k (Figure 1C).
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rotein amino acids, would have comprised 4800 pos-
ible combinations (12 × 400), but this was not at-
empted. Instead, a focused library comprising 11 di-
eptides was prepared based on the sequences of the
T-3 (and partly from NGF) β-turn regions [24] (Figure
B, substituent C).
Modeling was based on X-ray crystallographic studies
f the free neurotrophins [34–37], and neurotrophins
oupled with a Trk receptor fragment [38–40]. Most of
he dipeptides were modeled after i + 1 and i + 2 resi-
ues of β-turns (Figure 1C, dipeptides a–f). However, a
ew were also prepared corresponding to i to i + 1 resi-
ues (Figure 1C, dipeptides h, i, and j) and i + 2 to i + 3
esidues (Figure 1C, dipeptides g and k). The reason for
his was 2-fold. First, in solution, β-turns are dynamic
e.g., NGF crystals examined in two different studies
how different turn conformations). Second, diver-
ence of solution structures from the solid-state struc-
ure are likely when the ligands are docked with the Trk
eceptors [41]. For this study, there were 55 compounds
repared: 1Aa, 1Ad, 1Ba, 1Bd, 1Da, 2Aa, 2Ab, 2Ac,
Ad, 2Ae, 2Af, 2Ag, 2Ah, 2Ai, 2Ak, 2Aj, 2Ca, 2Cb, 2Cc,
Cd, 2Ce, 2Cf, 2Cg, 2Ch, 2Ci, 2Cj, 2Ck, 3Aa, 3Ab, 3Ac,
Ad, 3Ae, 3Ah, 3Aj, 3Ak, 3Ba, 3Bb, 3Bc, 3Bd, 3Be,
Bg, 3Bh, 3Bi, 3Bj, 3Bk, 3Ca, 3Cb, 3Cc, 3Cd, 3Ce, 3Cg,
Ch, 3Ci, 3Cj, and 3Ck. For comparison, the structure
f the first reported [26] peptidomimetic TrkA ligand D3
s shown (Figure 1D).
gonism in Trophic Survival Assays
he 55 peptidomimetics were tested for agonism in as-
ays of cell survival, using the quantitative MTT
ethod. Cells cultured in serum-free media (SFM) die
y apoptosis. The survival-inducing effect can be mea-
ured by the ability of peptidomimetics to protect cells
rom apoptosis selectively in a receptor-dependent and
ose-dependent manner. Also, peptidomimetics were
ested in combination with 0.1 nM of the corresponding
eurotrophin. This suboptimal concentration of neuro-
rophins affords suboptimal protection (w25%), and
herefore it is possible to measure potentiation of activ-
ty where the peptidomimetics enhance survival above
5%. We identified 14 compounds that, at 50 M or
ower concentrations, afford significant (p % 0.01) in-
rinsic trophic activity (in the absence of neurotrophin)
nd/or potentiate the trophic action of 0.1 nM neuro-
rophin (Table 1).
Peptidomimetics 1Ad (row 2), 3Ce (row 9), 3Ck (row
1), 1Aa (row 12), and 1Ba (row 13) have intrinsic tro-
hic activity selective for TrkC. All of these trophic
gents, except 1Ad, can also potentiate the survival-
romoting effect of 0.1 nM NT-3 on TrkC. Peptidomi-
etics that have no intrinsic trophic activity, but which
electively potentiate the survival-promoting effect of
.1 nM NT-3 on TrkC, include 3Aa (row 3), 3Ba (row 5),
Bg (row 6), 3Bi (row 7), and 3Cg (row 10).
None of the peptidomimetics afford selective trophic
rotection to TrkA-expressing cells, and none potenti-
te the effect of 0.1 nM NGF on TrkA.
Some peptidomimetics are trophic for both TrkA- and
rkC-expressing cells. These include 3Ak, 3Ca, 3Ac,
nd 3Ae. All these peptidomimetics also potentiate the
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1017Figure 1. Library and Library Code
(A) Code for numbered β-turn backbones 1,
2, and 3.
(B) Code for capital letter X substituents A,
B, C, D.
(C) Code for dipeptide (R1, R2) substituents.
(D) Example 3Ae, and published mimetic D3.survival-promoting effect of 0.1 nM NT-3 on TrkC. In
control assays, we demonstrated that cell survival is
Trk receptor-dependent because wild-type NIH-3T3
cells are not protected from death, and the survival-
promoting effect of unrelated growth factors EGF and
β-FGF are not affected either (data not shown).
Overall, the activity of the 14 agonistic peptidomimet-
ics could be divided into the following four classes: (1)
trophic selectivity toward TrkC, but do not potentiate
0.1 nM NT-3 (1Ad); (2) trophic selectivity toward TrkC,
and which synergistically potentiate 0.1 nM NT-3 (3Ce,
3Ck, 1Aa, and 1Ba); (3) trophic selectivity toward TrkC
only as potentiators of NT-3 (3Aa, 3Ba, 3Bg, 3Bi, and
3Cg); and (4) trophic agonists of both TrkC and TrkA
(3Ak, 3Ca, 3Ac and 3Ae). These peptidomimetics po-
tentiate NT-3, but do not potentiate NGF.
In some cases, the potentiation is synergistic and en-
hances suboptimal NT-3 from w25% to w100%, which
is optimal and equivalent to 2 nM NT-3 (e.g., 3Ac, 3Ae).
Four of the 14 agonistic peptidomimetics (1Aa, 1Ba,
3Ac, and 3Ae) afford statistically significant trophic sur-
vival at concentrations of 10 M or lower (Table 1).
Signal Transduction and Receptor Activation
We performed receptor pTyr assays after exposing
cells to each single ligand for 20 min (peptidomimetics
at 50 M, and NTFs at 0.1 nM and 2 nM) to confirm the
agonistic activity and the selectivity of the peptidomi-
metics toward TrkC or TrkA (Figure 2). Peptidomimetics
1Aa and 1Ba induce significant (p % 0.05) TrkC-pTyr,
and do not activate TrkA. Peptidomimetic 3Ac induces
significant (p% 0.05) TrkC-pTyr and TrkA-pTyr. The data
for these three compounds are consistent with the pre-
ceding survival assays.
Peptidomimetic 3Ae induces robust TrkC-pTyr, anddoes not activate TrkA. These data are inconsistent
with the preceding survival assays, in which 3Ae sup-
ports TrkA-mediated survival (Table 1). Likely, the 20-
min time point selected for the pTyr assay is not appro-
priate for detecting TrkA-pTyr induction by 3Ae (see
Kinetics of Activation, below).
Peptidomimetics 1Ad and 3Ba also induce signifi-
cant TrkC-pTyr, as expected. Unexpectedly, 1Ad and
3Ba also induce significant and robust TrkA-pTyr. TrkA
activation was unexpected because 1Ad and 3Ba are
selectively trophic for TrkC-expressing cells (Table 1).
Differentiation Assays
The finding that 1Ad and 3Ba induce TrkA-pTyr without
affording TrkA-mediated trophic survival leads to the
hypothesis that signals could result in neuritogenic dif-
ferentiation. The rationale for this prediction was that
NT-3 activation of TrkA preferentially results in neurito-
genesis in some cells [42]. Neuritogenesis by agonistic
peptidomimetics (at 50 M concentrations, in the ab-
sence of neurotrophins) was tested in differentiation
assays, using PC12 cells (TrkA+p75+++) or nnr5-TrkC
(TrkC+p75+++) cells (Figure 3A; summarized in Figure 3B).
Untreated nnr5-TrkC cells are somewhat more dif-
ferentiated than untreated PC12 cells, but NT-3 can in-
duce their differentiation in a dose-dependent manner.
Peptidomimetics 1Aa, 1Ad, 3Aa, 3Ac, 3Ae, 3Ba, and
3Ca induced significant (p < 0.01) differentiation of
nnr5-TrkC cells.
Untreated PC12 cells are undifferentiated, and NGF
induces differentiation in a dose-dependent manner.
Peptidomimetics 1Ad, 1Ba, 3Ac, and 3Ba induced sig-
nificant (p < 0.01) differentiation of PC12 cells com-
pared to untreated cells. These data indicate that the
TrkA-pTyr induced by 1Ad and 3Ba affords neuritogenic
differentiation without affording trophic survival.
Chemistry & Biology
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NIH-3T3 TrkA Cells NIH-3T3 TrkC Cells
Row Code Dose (M) SFM +NGF low SFM +NT-3 low
1 Untreated 0 24 ± 2 0 26 ± 3
2 1Ad −1 ± 1 23 ± 1 20 ± 1 38 ± 2
3 3Aa −4 ± 2 7 ± 2 4 ± 1 54 ± 1
4 3Ak 9 ± 1 30 ± 1 16 ± 4 90 ± 5
5 3Ba 2 ± 2 33 ± 2 −1 ±1 54 ± 4
6 3Bg −5 ± 3 19 ± 2 −3 ± 1 39 ± 1
7 3Bi −1 ± 3 2 ± 1 −2 ± 1 52 ± 1
8 3Ca 7 ± 1 30 ± 2 12 ± 3 76 ± 7
9 3Ce 2 ± 1 18 ± 1 7 ± 2 69 ± 8
10 3Cg 1 ± 1 23 ± 1 2 ± 1 59 ± 3
11 3Ck 2 ± 1 19 ± 1 9 ± 2 68 ± 5
12 1Aa 0.4 −5 ± 5 20 ± 4 1 ± 0 29 ± 5
2 −5 ± 4 20 ± 3 8 ± 1 29 ± 2
10 −4 ± 5 21 ± 3 13 ± 1 35 ± 3
50 1 ± 3 23 ± 1 17 ± 2 71 ± 5
(continued)
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1019None of the other agonists in the trophic survival as-
says induced significant differentiation (e.g., 3Ak). Only
one compound, 3Cg, was not tested in the differentia-
tion assay.
Kinetics of Activation
We hypothesized that the 20 min time point selected
for the pTyr assay may not be always appropriate for
detecting TrkA-pTyr by peptidomimetics, although it is
an appropriate time point for NGF. For example, 1Ba
affords differentiation of PC12 cells (Figure 3B), but
does not afford detectable TrkA-pTyr in NIH-TrkA cells
after 20 min of exposure (Figure 2).
Thus, a time course of Trk phosphorylation kinetics
was done for 1Ba (50 M), using NIH-TrkA (TrkA+++)
(summarized in Figure 3C), and using NIH-TrkC
(TrkC+++) and PC12 (TrkA+p75+++) cells (Figure 3D).
NT-3 and NGF (10 nM) were used as positive controls
and to standardize the assay versus untreated (no li-
gand) negative controls.
On NIH-TrkA cells, 1Ba activates TrkA with rapid and
transient kinetics, whereas NGF activates with rapid
and sustained kinetics and with higher potency. 1Ba
exposure induces TrkA-pTyr after 5 min; the activity is
still significant after 10 min, but is insignificant after 20
min. Interestingly, on PC12 cells, 1Ba activates TrkA
with rapid and sustained kinetics, and with a potency
w35% that of NGF (Figure 3D). On NIH-TrkC cells, both
1Ba and NT-3 activate TrkC with rapid and sustained
kinetics, although the potency of 1Ba is much lower
than that of NT-3 (Figure 3D).
Thus, 1Ba seems to be a better TrkA agonist for PC12
cells than for NIH-TrkA cells, even though the latter ex-
press higher density of TrkA receptors. Because it is
possible that coexpression of p75 receptors in PC12
cells may be key in agonism by 1Ba, this was tested in
preliminary studies using NIH-TrkA cells infected withTable 1. Continued
NIH-3T3 TrkA Cells NIH-3T3 TrkC Cells
Row Code Dose (M) SFM +NGF low SFM +NT-3 low
13 1Ba 0.4 −3 ± 2 19 ± 2 0 ± 2 32 ± 2
2 −5 ± 1 22 ± 2 1 ± 3 35 ± 2
10 8 ± 5 32 ± 1 6 ± 2 44 ± 3
50 4 ± 3 15 ± 1 11 ± 1 54 ± 5
14 3Ac 0.4 6 ± 3 29 ± 3 0 ± 1 37 ± 3
2 5 ± 1 30 ± 4 −1 ± 1 43 ± 9
10 7 ± 2 30 ± 8 8± 2 61 ± 26
50 13 ± 3 33 ± 7 15 ± 3 97 ± 6
15 3Ae 0.4 3 ± 2 27 ± 2 2 ± 1 27 ± 4
2 6 ± 2 29 ± 1 4 ± 1 34 ± 3
10 9 ± 1 27 ± 3 10 ± 1 51 ± 7
50 10 ± 2 27 ± 1 20 ± 3 111 ± 10
Cells were cultured in SFM supplemented with control or peptidomimetics (the concentrations indicated, or 50 M where not indicated),
either with no neurotrophins (SFM) or with 0.1 nM of the corresponding neurotrophin (NGF for TrkA cells; NT-3 for TrkC cells). Survival was
measured in MTT assays, and was calculated relative to 2 nM neurotrophin (100% protection). Results shown are average ± SEM (n = 4),
from at least three independent experiments. Bold numbers indicate statistically significant cell survival compared with the corresponding
untreated cells (p % 0.01).p75-expressing adenoviruses [10]. FACScan phenotyp-
ing showed that NIH-TrkA+p75 cells expressed high
density of both receptors (TrkA+++p75+++) (data not
shown). On NIH-TrkA+p75 cells, 1Ba activates TrkA
with rapid and sustained kinetics, and with relatively
higher potency (data not shown).
Together, these data suggest that 1Ba is a TrkA ago-
nist independent of p75 coexpression (e.g., 1Ba by
itself induced TrkA-pTyr in NIH-TrkA cells), but that p75
expression can affect the kinetics of the TrkA signaling
by 1Ba. This could conceivably happen either because
p75 is a known regulator of TrkA activity [10, 43], be-
cause 1Ba binds to p75, or it binds to a putative hetero-
meric TrkA-p75 receptor complex. Additionally, these
data suggest that TrkA activation by 1Ba leads to cellu-
lar differentiation only. Indeed, further survival assays
using PC12 cells confirmed that 1Ba did not afford cel-
lular survival (data not shown). Similar kinetic studies
were not carried out with 3Ae, but it is likely that, in
analogy to 1Ba, differential kinetics account for its abil-
ity to afford TrkA-mediated survival (Table 1) without
detectable TrkA-pTyr after 20 min of exposure (Fig-
ure 2).
Direct Receptor Binding Studies
Analogs of some agonistic peptidomimetics were syn-
thesized in their fluorescinated form (peptidomimetic-
FITC). These labeled analogs were used in quantitative
FACScan assays measuring direct binding to NIH-TrkC
cells, NIH-TrkA cells, or negative-control wild-type NIH-
3T3 cells to determine Trk-receptor specificity. In addi-
tion, NIH-3T3 fibroblasts expressing p75 receptors
(NIH-p75) and nnr5 cells were also studied to address
the possibility that the labeled peptidomimetics may
bind to p75 (data not shown). Anti-TrkA mAb 5C3 and
anti-TrkC mAb 2B7 were used as positive controls.
Two examples of FACS profiles (3Ac-FITC and 3Aa-
Chemistry & Biology
1020Figure 2. Receptor Tyrosine Phosphorylation
Induced by Peptidomimetics
(A) NIH-TrkC or NIH-TrkA cells were exposed
to the indicated ligand (peptidomimetics
alone at 50 M or NTFs alone as indicated),
and detergent lysates were analyzed by
Western blotting with anti-pTyr mAb 4G10.
Data were quantified by densitometry, rela-
tive to 2 nM NTF, and are presented as
average (n = 3) ± SD. NTF = neurotrophin
(NT-3 for NIH-TrkC and NGF for NIH-TrkA).
(B) Representative examples of compounds
inducing Trk-pTyr.FITC) are shown in Figure 4. Compound 3Ac-FITC
bound to NIH-TrkA and NIH-TrkC cells, but wild-type
NIH-3T3 cells did not bind 3Ac-FITC (Figure 4A), nor
did they bind antireceptor mAbs (data not shown). This
compound is bioactive at both TrkA and TrkC, hence
the binding data are consistent with the bioassays.
Compound 3Aa-FITC binds only to NIH-TrkC cells and
does not bind to NIH-TrkA (Figure 4B) or to wild-type
NIH-3T3 cells (data not shown). This compound is bio-
active only on cells expressing TrkC, hence binding
data are consistent with bioassays.
Table 2 summarizes the direct binding assays with
fluoresceinated peptidomimetics. 3Ai-FITC has no sig-
nificant TrkA or TrkC binding. This compound was
made as a negative control because 3Ai does not acti-
vate TrkA or TrkC in bioassays. 3Aa-FITC binds only
to TrkC. This binding is consistent with TrkC-selective
activity in bioassays using the unlabeled parental com-
pound. 3Ac-FITC, 3Ae-FITC, 1Ad-FITC, and 3Ak-FITC
bind TrkC and TrkA. Binding data are consistent with
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ells. In bioassays using the unlabeled parental 1Aa
ompound, only TrkC is activated. It is possible that
Aa binds TrkA without activating it efficiently, much
ike NT-3 does [42, 44]. However, we cannot rule out
hat the FITC adduct could have altered the binding
roperties of 1Aa or other compounds.
Other FACScan binding assays versus NIH wild-type,
nr5, and NIH-p75 cells demonstrated that the FITC-
abeled peptidomimetics did not bind p75-expressing
ells significantly above background (data not shown).
ogether, these data suggest that the FITC-labeled
eptidomimetics (and likely the corresponding unla-
eled parental peptidomimetics) do not bind the p75
eceptor. If the unlabeled compounds do bind p75, then
t must be that the FITC label otherwise blocks their
inding. Given the possibility that the FITC label may
ave prevented p75 binding in the FACS assays, and
ecause there are no reliable and robust functional as-
ays for p75, we could not correlate lack of p75 bindingwith lack of p75-mediated activity.
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1021Figure 3. Cellular Differentiation Induced by
Peptidomimetics
(A) Representative assays of PC12 (TrkA+) or
nnr5-TrkC cells (TrkC+) differentiation. NTF =
0.1 nM NT-3 or NGF.
(B) Quantitative summary (±SD) and statisti-
cal analyses. The letters under the graph (A;
C; and A,C) indicate statistically significant
differentiation compared with untreated (p%
0.01). Note that the untreated group (labeled
“none”) in each cell line has a different back-
ground. Cells were plated with ligands or
controls, and differentiation 3 days after
plating was determined as percent of cells
with neurites (>2 cell bodies long). Four inde-
pendent plates were scored, with an average
cell count of 203 ± 33 per condition.
(C) Summary of kinetic studies of TrkA-pTyr
by 1Ba in NIH-TrkA cells (n = 7 independent
gels standardized to protein loading ±SD).
(D) Examples of TrkA-pTyr or TrkC-pTyr
Western blots for NIH-TrkA cells, PC12 cells,
or NIH-TrkC cells.Indirect Receptor Binding Studies
Ligand competition assays were used to further define
peptidomimetic binding to Trk receptors. MAb 5C3 is
an agonistic antibody directed to the TrkA-IgC2 hot
spot, and mAb 2B7 is an agonistic antibody directed to
the TrkC-IgC2 hot spot. The agonistic peptidomimeticswere tested for competitive block of mAb,hot spot in-
teractions in binding assays.
Cells were treated with neurotrophins or peptidomi-
metics, followed by labeling with fluorescein-tagged
5C3 or 2B7 mAbs. Analyses were done by FACScan,
and percent inhibition of binding (average ± SD, n =
Chemistry & Biology
1022Figure 4. Receptor Binding Specificity Data
(A and B) FACScan binding assays with FITC-peptidomimetic. The
indicated cells were bound with ligand (50 M), and washed. Data
are representative of three independent assays.
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c3) were calculated as a change in mean fluorescence
channel (MCF) with respect to untreated cells. The pos-
itive-control NGF blocked 5C3,TrkA by 27 ± 4%, and
NT-3 blocked 2B7,TrkC interactions by 37 ± 3% (signifi-
cant, p % 0.05).
Peptidomimetics 3Ba, 3Bg, and 3Bi blocked 2B7,
TrkC binding by 57% ± 1%, 27% ± 3%, and 30% ± 2%,
respectively. Blocking was significant (p % 0.05) and
selective for TrkC because 5C3,TrkA binding was not
affected. We estimate a Kd of w4 M for 3Ba, based
on its IC50 toward mAb 2B7 (where w1500-fold molar
excess 3Ba competes 50% of mAb 2B7 [Kd w6 nM]).
Although it is possible that inhibition is steric rather
than competitive, these data further support the notion
that at least 3Ba, 3Bg, and 3Bi are true receptor ligands
binding TrkC at or near the IgC2 hot spot.
In built-in controls, none of the other agonistic pepti-
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Fomimetics blocked 2B7,TrkC binding or 5C3,TrkA
inding significantly. Lack of competition by other ago-
istic peptidomimetics may simply indicate that they
ind the receptor elsewhere outside the mAb hot spots,
r that the peptidomimetic affinity is too low to com-
ete with a high-affinity bivalent mAb.
iscussion
n this study, we expand on the rational development of
he first reported peptidomimetic small molecule TrkA
gonist, termed D3. While D3 is a partial agonist of
rkA, its intrinsic activity is relatively low and it is best
evealed when acting as a synergistic potentiator of
GF [26]. We therefore completed a study for pepti-
omimetic analogs related to D3 and the neurotrophin
-turns.
Functional assays showed that peptidomimetics re-
orted here have intrinsic partial agonistic activity in
he absence of exogenous neurotrophins, and are
herefore improved agents compared to D3. Agonism
an be selective toward TrkC only, or both TrkC and
rkA. Agonism can comprise full neurotrophic signals
survival and differentiation) or discrete neurotrophic
ignals (either survival or differentiation).
Binding assays showed that the functional peptido-
imetics are bona fide artificial ligands and bind to Trk
eceptors. Some peptidomimetics are specific for TrkC
nd some bind both TrkC and TrkA. Some of the pepti-
omimetics bind at Trk receptor epitopes defined by
gonistic antireceptor mAbs [33, 45], and these do-
ains are also defined as “hot spots” by reported re-
eptor mutagenesis, neurotrophin binding studies and
unctional studies [9, 10].
The FITC-labeled peptidomimetics did not bind p75
eceptors. However, we cannot rule out that the FITC
dduct could have altered the binding properties of the
ompounds. If the unlabeled compounds do bind p75,
hen it must be that the FITC label blocks their binding.
iven the possibility that the FITC label may have pre-
ented p75 binding in the FACS assays, and because
here are no reliable and robust functional assays for
75, we could not correlate lack of p75 binding with
ack of p75-mediated activity. However, we noted that
Ba affords sustained and more robust Trk-pTyr in cells
oexpressing TrkA and p75. Thus, while overall the data
uggest that expression of p75 is not necessary for
eptidomimetic binding and activity (e.g., NIH-TrkC and
IH-TrkA do not express p75), and expression of p75
oes not interfere with function (e.g., PC12 cells and
nr5-TrkC cells expressing p75 respond in bioassays),
e cannot rule out that expression of p75 could regu-
ate binding or function (see below for more discussion
n this issue). Indeed, previous reports have shown that
ryptic Trk “hot spots,” where NGF docks and acti-
ates, are unmasked when p75 is coexpressed [9, 10].
hus, the definitive answer to whether the compounds
ind p75 may require further formal proof.
Table 3 summarizes the biological, receptor selectiv-
ty, and binding data. This table highlights that, gen-
rally, the binding specificity and the biological data
orrelate well, and presents some interesting findings.
or example, binding can occur without activation (e.g.,
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Mean Channel Fluorescence
Structure Compound NIH-TrkA NIH-TrkC
5C3 or 2B7, control mAb 364 ± 7 175 ± 31
3Aa-FITC 42 ± 15 73 ± 11
3Ac-FITC 52 ± 11 79 ± 10
3Ae-FITC 41 ± 10 66 ± 5
3Ak-FITC 44 ± 26 62 ± 18
1Ad-FITC 52 ± 24 90 ± 31
1Aa-FITC 56 ± 5 65 ± 7
3Ai- FITC 9 ± 5 18 ± 9
FACScan binding assays with FITC-peptidomimetic. Cells were bound with ligand (50 M), washed, and studied. Data was acquired and
analyzed by FACScan/CellQuest, with backgrounds subtracted. Mean channel fluorescence (MCF) ± SD, n = 3.1Aa binds TrkA but does not activate it). Also activation
(pTyr) of a receptor can lead to either or both differenti-
ation and survival (e.g., 1Ba induces TrkA-pTyr and
leads to cellular differentiation but not to survival). In
part, the biological outcome depends on the kinetics of
receptor pTyr (e.g., 1Ba), and likely also depends on
ligand-dependent receptor internalization, as was re-
ported elsewhere for other TrkA agonists [46, 47].
The Screening Process
A total of 26 out of the 55 designed peptidomimetics
were biologically active (14 agonists described in this
report, and 12 antagonists [unpublished data]). The
high efficacy of a focused library suggests that, for
some targets (such as cell surface receptors), this ap-
proach may be more desirable than random screening
of larger libraries.
The main advantages of a focused library are: (1)
compounds insoluble in physiological buffers and com-
pounds that are toxic are quickly discarded; (2) me-
dium-throughput trophic assays can use live cells, and
can include several cell types to account for receptor
selectivity; (3) potentiation and antagonism of neuro-trophins can be assayed simultaneously; (4) direct
binding and competitive binding assays can be per-
formed using labeled ligands; and (5) more elaborate
neuritogenic assays can be performed in a reduced
pool of candidates. A typical high-throughput screen
(e.g., based on receptor pTyr or based on competition
of ligand binding) would have missed compounds, such
as 3Ba, that potentiate neurotrophin action.
One of our binding screens was based on peptidomi-
metic competition of mAbs directed to Trk hot spots.
This high-throughput screen is desirable because it se-
lects compounds that likely bind to functional receptor
ectodomains, and it can assess target selectivity be-
cause anti-TrkA and anti-TrkC mAbs can be screened
simultaneously. While the overall efficacy of this partic-
ular screen is very high, we should note that simple
docking at a receptor hot spot is not necessarily suffi-
cient for activation, and that ligands generally must
also induce a receptor conformational change.
Electrostatic and Side Chain Considerations
Please see Supplemental Data for structures and mod-
els and the electrostatic maps of some compounds.
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Antibody
Code aa Scaffold X Survivala pTyrb Differentiationc Bindingd Displacement
1Aa IK amine amine Cpt C nnr5-TrkC AC −
1Ad EK amine amine Ct CA PC12; nnr5-TrkC AC nt
1Ba IK amine guanadine Cpt C PC12 nt nt
3Aa IK ether amine Cp nt nnr5-TrkC C nt
3Ac GK ether amine AC AC PC12; nnr5-TrkC AC nt
3Ae IR ether amine AC C nnr5-TrkC AC nt
3Ak RG ether amine AC nt − AC nt
3Ba IK ether guanadine Cp AC PC12; nnr5-TrkC nt C
3Bg KG ether guanadine Cp nt − nt C
3Bi KT ether guanadine Cp nt − nt C
3Ca IK ether MeSO2NH AC nt − nt nt
3Ce IR ether MeSO2NH Cpt nt − nt nt
3Cg KG ether MeSO2NH Cp nt − nt nt
3Ck RG ether MeSO2NH Cpt nt − nt nt
“Survival” refers to studies on NIH-TrkC or NIH-TrkA cells; “pTyr” refers to studies on NIH-TrkA and NIH-TrkC, except 1Ba, which was studied
in other cells; “Binding” refers to studies using FITC-analogs, thus the “X” substituents of these labeled peptidomimetics are different than
the parental peptidomimetics used in the other studies; “Antibody Displacement” assays were done with parental peptidomimetics and mAbs
5C3 or 2B7 directed to IgC2 (D5) receptor hot spots of TrkA and TrkC, respectively.
Abbreviations: aa, amino acid; AC, the compound has activity for both receptors but no preference for TrkA versus TrkC; C, selective activity
at TrkC; CA, compound has activity for both receptors but stronger activation of TrkC (e.g., pTyr 1Ad and 3Ba); nt, not tested; p, potentiation;
t, intrinsic trophism; −, no effect.
a See Table 1.
b See Figures 2 and 3.
c See Figure 3.
d See Figure 4.Electrostatic or conformational mechanisms may ac-
count for the following observations highlighted below:
(1) the apparent negative influence of the sulfur or the
appended carboxylic acid (group 2 compounds are not
agonistic); (2) the possible role of the “X” substitution/
modification in affecting ligand selectivity; and (3) the
possible role of the amine backbone in affecting biolog-
ical activity.
The sequence “IK” is present in 5/14 agonistic pepti-
domimetics. The sequences “IR,” “GK,” and “RG” are
present in five of the remaining nine agonists, and “EK,”
“KT,” and “KG” comprise the rest.
With respect to “IK” side chains, 1Aa and 3Aa display
the dipeptide “IK” but in different backbones: amines
(1Aa) or ethers (3Aa). Functionally 1Aa and 3Aa are
specific activators of TrkC, although the derivative
FITC-1Aa does bind to TrkC. Two related compounds
are 1Ba and 3Ba, which display “IK” in the same re-
spective backbones as 1Aa and 3Aa but with a different
“X” substituent (a guanidine instead of an H) (Figure 1).
1Ba and 3Ba activate both TrkC and TrkA. Either the
“X” substitution in 1Ba and 3Ba or the FITC-adduct at
the “X” position in FITC-1Aa may be responsible for
their reduced receptor specificity. Likewise, the “X”
substitution of 3Ca may be responsible for reduced re-
ceptor specificity. 3Ca is similar to 3Aa, and displays
the dipeptide “IK” with an ether backbone, but has a
methyl sulfonamide “X” substituent. 3Ca activates TrkC
and TrkA. These data suggest that while the nature of
the cyclic backbone allows some modifications with no
loss of activity or selectivity, the “X” substitution or
modification may regulate selectivity.
With respect to “EK” and “GK” side chains, com-
pound 1Ad is similar in structure to 1Aa (both back-
bone and “X” substituent) but displays the dipeptide
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rEK” instead of “IK”. Likewise, compound 3Ac is re-
ated to 3Aa but displays the dipeptide sequence “GK”
nstead of “IK.” Both 1Ad and 3Ac activate TrkC and
rkA, whereas 1Aa and 3Aa are TrkC-selective. These
ata suggest that the “EK” dipeptide may be less re-
eptor-specific than “IK.” Again, the importance of the
X” substituent may be demonstrated with the inactive
ompounds 1Bd and 3Bc (related to 1Ad and 3Ac, but
ith X = guanidine). On the other hand, when the “X”
osition is derivatized with the larger FITC moiety (e.g.,
ITC-1Ad), the compound still binds to TrkA and TrkC,
uggesting that this substitution is not absolutely
ritical.
Other related compounds, 2Ad, 2Cd, 3Ad, 3Bd, and
Cd, also display the dipeptide “EK” but on different
ackbones (sulfide or ether, instead of amine), and they
re not agonistic. These data suggest that the amine
ackbone may be relevant to biological activity.
It may also be significant that the aromatic substitu-
nts in the active peptidomimetics in the A and B series
re also cationic (amine and guanidine). In contrast, the
eries 2 compounds were relatively less active in all the
ssays performed, and all have a pendant carboxylic
cid. Series 2 compounds also all have endocyclic
-atoms, so lack of activity could be coincidental. Be-
ause compounds segregating the influence of endo-
yclic S-atoms versus the pendant carboxylic acid are
acking, the influence of each change cannot be fully
ssessed. However, it does appear that positively
harged peptidomimetics were more active in the bind-
ng assays.
It is informative to compare the structures of the
ctive peptidomimetics with the sequences of the
mino acids around the turn regions of human and mu-
ine NGF and NT-3. NGF turn 1 has sequence D30IKG33
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NGF turn 3 has sequence D93EKQ96, D93GKQ96, or
D93NKQ96, depending on species. For NT-3, turn 1 is
DIRG, turn 2 is KTGN, and turn 3 is ENNK. Most of the
active compounds identified tend to contain lysine or,
to a lesser degree, arginine. This correlates with the
sequences of the 31–32 and 94–95, i + 1/i + 2, residues
of the turn regions of NGF, both of which contain lysine.
Thus, one neurotrophin pharmacophore could be de-
fined as “IKGK” or “IRG” side chains displayed on a
β-turn backbone. It is noteworthy that another pharma-
cophore, “DEK,” is found both in the first and in the
fourth loop regions of NT-3 and NGF. However, this ob-
servation partially reflects the loop sequences targeted,
and does not per se exclude other regions of the neuro-
trophins. The Arg103 of NGF is present in all neurotroph-
ins as part of the so-called “conserved patch” [48], and
is thought to increase binding affinity without signifi-
cantly influencing the specificity of binding. Conse-
quently, it is conceivable that some or all of the pepti-
domimetics may not be mimicking the roles of the NGF
turn regions. They might instead tend to bind to the
regions of the TrkA receptors that would normally in-
teract with Arg103, and the data do not allow this possi-
bility to be discounted.
Several compounds (3Bg, 3Bi, 3Ce, and 3Ck) afford
only survival (no differentiation), and only through TrkC
receptors. These compounds encompass the dipeptide
sequences “KG,” “KT,” “IR,” and “RG,” respectively.
3Ak also affords only survival, but can act through both
TrkA and TrkC. 3Ak displays the sequence “RG,” as
does the related compound 3Ck. Hence, the amine in
3Ak reduces receptor specificity (3Ck is TrkC-specific).
3Ae activates TrkA and TrkC, whereas 3Ce is TrkC-spe-
cific. Both 3Ae and 3Ck display the sequence “IR.” As
above, the methyl sulfonamide substitutent in 3Ae re-
duces receptor specificity. None of the methyl sulfon-
amide substituents afford differentiation, but they do
afford survival. While the backbone is less sensitive to
substitutions and accepts amines or ethers, the sulfide
backbone (which closely mimics the ether backbone)
always resulted in inactive compounds.
Signal Transduction and the Role
of p75 Coreceptors
It is impressive that a small molecule ligand can induce
receptor pTyr and activate both trophic and neurito-
genic signals, in the absence of neurotrophins. We also
show that a peptidomimetic with both trophic and neu-
ritogenic signals can be modified to generate an analog
that affords discrete signals such as trophic survival
only (e.g., 3Ak, 3Bg, 3Bi, 3Ca, 3Ce, and 3Ck). By com-
parison, both NT-3 and NGF bind TrkA but do so at
relatively nonoverlapping sites. NGF binding to TrkA ac-
tivates survival and differentiation signals, whereas
NT-3 binding to TrkA as a heterologous ligand activates
differentiation but does not activate strong trophic sig-
nals [42]. The potency of TrkA activation also depends
on coexpression of p75 receptors, with NGF signaling
being enhanced and NT-3 signaling being inhibited [49].
Peptidomimetics 1Ad and 3Ba induce TrkA phos-
phorylation leading only to differentiation and, there-
fore, behave much like NT-3. However, unlike NT-3, 1Adand 3Ba seem to be unaffected by coexpression of p75
in PC12 cells. In addition, other data demonstrate that
peptidomimetic binding and activity are not dependent
on p75 (e.g., some compounds are active on NIH-TrkC
cells lacking p75).
As summarized in Table 3, initial studies of receptor
binding and biological activity did not correlate well for
compounds 1Ba and 3Ae. Kinetic studies were carried
out for 1Ba, but not for 3Ae. Compound 1Ba signals
through TrkA and TrkC in a manner that is independent
of, but can be regulated by, p75 coexpression. 1Ba acti-
vates TrkC with fast and sustained kinetics leading to
survival, independent of p75 coexpression (e.g., NIH-
TrkC cells). However, in NIH-TrkA cells, 1Ba activates
TrkA with transient kinetics that do not afford survival,
whereas in cells coexpressing TrkA and p75, it activates
TrkA with fast and sustained kinetics and higher po-
tency; activity that, in PC12 cells, result in differenti-
ation.
Whether or not these data mean that 1Ba binds/acti-
vates both TrkA and p75 is inconclusive. We favor the
interpretation that p75 acts as a regulator of peptidomi-
metic-dependent Trk activity because both the potency
of activation and the type of biological response to TrkA
activation by NGF and NT-3 are known to depend on
coexpression of p75 receptors [49]. Additionally, there
is no evidence that ligand-bound p75 is a prodifferenti-
ation receptor in PC12 cells. Rather, the simplest expla-
nation is that these peptidomimetics have distinct ki-
netics of receptor activation (or internalization), leading
to distinct biological outcomes of survival or differentia-
tion. Indeed, ligand-dependent Trk receptor internaliza-
tion is known to determine the biological outcome [46,
47]. Also, we cannot rule out that the compounds in-
duce or stabilize receptor dimerization or clustering
[50], as has been shown elsewhere [27], or that the
compounds interact with two independent receptor
hot spots.
Conclusions
Altered function of the neurotrophins or their receptors
is relevant to pathologies [1, 3–5], but clinical trials have
been disappointing [7] due to in vivo instability, side
effects produced by the activation of signals that were
not intentionally targeted, and drawbacks inherent to
proteins when used as drugs. Thus, small molecule
peptidomimetics of the neurotrophins that have better
pharmacokinetic properties may be useful therapeu-
tics. Another potentially attractive feature is that small
molecules could target receptors at single activation or
regulatory hot spots (e.g., only Trk IgC2 or only LRM
subdomains), thus affording agents with high Trk selec-
tivity, partial Trk agonism, and potentially excluding
binding to p75. From a drug development perspective,
it may be desirable to have small molecules that uncou-
ple trophic and neurotigenic signals because they can
be used as selective therapeutics in conditions where
a single activity is required. For example, in stroke or
Alzheimer’s disease, it may be desirable to support ex-
isting neurons from death without inducing connec-
tions de novo that might be dysfunctional. The screen-
ing approaches we describe here can be easily adapted
to other cell surface receptors.
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Our findings demonstrate that a small molecule pep-
tidomimetic ligand of TrkA Trk tyrosine kinase re-
ceptors can activate selectively by binding at the ec-
todomain, without apparent interactions with p75
coreceptors. We also show that engaging a receptor
“hot spot” is sufficient to induce a functional re-
sponse, and that small molecule ligands can activate
discrete or multiple signal transduction pathways.
Some peptidomimetics induce both neurotrophic ac-
tivities of survival and differentiation, while other pep-
tidomimetics afford either survival or differentiation.
These data suggest that certain receptor ectodomain
“hot spots” may be responsible for specific signals.
Of conceptual interest is the high rate of success of
the design and screening approach, which suggests
that a focused library designed specifically to target
receptor hot spots may be a useful generic method
for identifying functional ligands. This work helps us
to understand how the neurotrophins function through
Trk receptors, and is a step forward in the search for
small, stable molecules with selective agonistic activ-
ity and possible therapeutic potential in cholinergic/
cognitive (TrkA) or motor neuron (TrkC) disorders.
Experimental Procedures
Preparation of Template Compounds 1–3 and Their Derivatives
The β-turn backbone (Figure 1) comprises an organic moiety and a
dipeptide moiety R1 R2 within a turn. The backbone has a function-
ality to generate diversity with any of three substituents: cyclic
amines, cyclic sulfides, or cyclic ethers (Figure 1A). Compounds
1–3 can be made on a solid phase, in parallel, to give small librar-
ies. The “X” functionality can be derivatized with four substituents
to generate diversity: amino, guanidine, N-methyl sulfonamide, and
arginine (Figure 1B). The amino (X = NH2) backbone derivatives 1A,
2A, and 3A were prepared on resin bearing the side chain-pro-
tected cyclic peptide with nitro groups, as previously described
[30, 33, 51], and purified by preparative HPLC. The guanidine (X =
C(=NH)NH2) backbone derivatives 1B, 2B, and 3B were prepared
on resin containing side chain-protected cyclic peptide. The resin
was swelled in CH2Cl2 for 30 min and treated with 10 Eq of N,N-
bis-BOC-1-guanylpyrazole in DMF (for 1 and 2) or 10 Eq of N,N-bis-
BOC-thiourea and 10 Eq of N-methyl-2-chloropyridinium chloride in
CH2Cl2 (for 3) for 1 day. After washing, the peptide was cleaved
from the resin by treatment with a mixture of 90% CF3CO2H, 5%
HSiEt3, and 5% H2O for 2 hr, filtered, and the crude peptide was
purified by preparative HPLC. The N-methyl sulfonamide (X =
SO2CH3) backbone derivatives 1C, 2C, and 3C were prepared on
resin containing side chain-protected cyclic peptide with amino
group. The resin was swelled in CH2Cl2 in a fritted syringe for 30
min and treated with 10 Eq of methanesulfonyl chloride, 10 Eq of
pyridine, and 1 Eq of 4-dimethylaminopyridine in CH2Cl2 for 1 day.
After washing, the peptide was cleaved from the resin as above,
filtered, and the crude peptide was purified by preparative HPLC.
The arginine-substituted (X = Arg) backbone derivative 1D was pre-
pared on resin containing side chain-protected cyclic peptide. The
resin was swelled in CH2Cl2 in a fritted syringe for 30 min and
treated with 4 Eq of FmocArg(Pmc)OH, 4 Eq of PyBrop, and 15 Eq
of 2,6-lutidine in CH2Cl2 for 20 hr. After washing, Fmoc protecting
group was removed with 20% piperidine. The peptide was cleaved
from the resin by treatment with a mixture of 90% CF3CO2H, 5%
HSiEt3, and 5% H2O for 10 hr, the crude peptide was triturated
using anhydrous ethyl ether and purified by preparative HPLC. All
compounds were analyzed as homogeneous single peaks by ana-
lytical HPLC (2%–40% B in 30 min), by MALDI MS, and by 1H NMR
(300 MHz, dimethylsulfoxide [DMSO]-d6) [33, 51], confirming the
expected structures.
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ireparation of Fluorescinated Compounds
esin supporting the side chain-protected cyclic peptidomimetics
ith amino group was swelled in CH2Cl2 for 30 min and treated
ith 4 Eq of Fmoc-β-Ala-OH, 4.6 Eq of PyBrOP and 15 Eq of 2,6-
utidine in CH2Cl2. After 20 hr of gentle shaking, the resin was
ashed and Fmoc was removed with 20% piperidine in DMF. The
esin was then treated with fluorescein 5-isothiocyanate (i.e., “iso-
er I,” 3 Eq), 5 Eq DIEA in CH2Cl2/DMSO (2:1) for 3 hr, washed
gain, and finally cleaved with a mixture of 90% TFA, 5% Et3SiH,
nd 5% H2O. After most of the cleavage cocktail was evaporated
n a stream of nitrogen. Anhydrous ethyl ether was added to precip-
tate the product, which was purified by preparative HPLC. Not all
ITC compounds were prepared, only agonists of interest.
eptidomimetic Solubility
ost of the compounds were soluble in physiological buffers, but
ome required up to 1.5% DMSO as solvent, which did not interfere
ith the binding assays or the bioassays. Peptidomimetics requir-
ng higher concentrations of DMSO were excluded because of pos-
ible toxicity. Vehicle was always used as control.
ell Lines
ell lines used were wild-type NIH-3T3 fibroblasts, NIH-3T3 stably
ransfected with human p140 trkC cDNA (NIH-TrkC), or NIH-3T3
ibroblast stably transfected with human p140 trkA cDNA (NIH-TrkA
ells). NIH-p75 fibroblasts were produced by infection with adeno-
iruses constructed to express p75 [10]. Rat PC12 pheochromocy-
oma cells express the p75 neurotrophin receptor and low levels of
rkA (TrkA+ p75+++), and can be induced to differentiate into neu-
ite-bearing cells by TrkA activation. The nnr5 cells are a variant of
C12 cells that have lost TrkA expression (TrkA− p75+++). The nnr5-
rkC cells are nnr5 cells stably transfected with human p140 trkC
DNA. The nnr5-TrkC cells express low levels of TrkC (TrkC+
75+++), and can be induced to differentiate into neurite-bearing
ells by TrkC activation.
ell Survival Assays
ell survival was measured quantitatively by the MTT assay and
ptical density (OD) readings, as previously described [46, 52], after
ulture in SFM. Cells in SFM die by apoptosis, but can be rescued
f supplemented with the appropriate neurotrophin if they express
unctional receptors. Wells were not supplemented (negative con-
rol), or were supplemented with suboptimal (0.1 nM) or optimal (2
M) concentrations of the indicated neurotrophins. Test peptidomi-
etics or vehicle were added to the two conditions above. Lack of
ffect on NIH-TrkA with effect on NIH-TrkC is evidence of selectiv-
ty. Trk receptor selectivity and lack of toxicity was assessed in
ild-type NIH-3T3 cells in SFM surviving to fibroblast growth factor
βFGF) or NIH-3T3 cells under normal growth conditions (5% se-
um). Lack of effect on βFGF or 5% serum-mediated survival is
vidence of Trk specificity. All assays were repeated independently
t least three times (n = 4–6 for each assay). MTT data are stan-
ardized to: 2 nM neurotrophin = 100% survival, and SFM = 0%
urvival, using the formula [(ODtest − ODSFM) × 100/(OD2 nM NTF −
DSFM)].
eurite Outgrowth Assays
eptidomimetics were tested for their ability to induce neurite out-
rowth in PC12 and nnr5-TrkC cells. Cells were incubated in com-
lete media without or with peptidomimetics alone (50 M) or neu-
otrophins alone (0.1 nM or 2 nM). Neurite outgrowth was measured
very 24 hr for 3 days. After 3 days, cells were fixed for 20 min with
% paraformaldehyde, washed two times with PBS, incubated at
oom temperature for 20 min with permeabilization solution (2%
SA, 0.3% TritonX, in PBS), and incubated for 1 hr at room temper-
ture with 1:200 dilution of FITC-anti-CD90 (Thy-1) (Pharmingen).
uantification was done by image analysis, from at least three in-
ependent assays, scoring an average of 203 ± 33 cells per each
ondition. Differentiation was scored morphologically, neurites be-
ng processes longer than two cell bodies.
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mAb 5C3 is an agonistic anti-TrkA IgG-C2 (D5) domain antibody
[45]. The mAb 2B7 [33] is an agonistic anti-TrkC IgG-C2 (D5) do-
main antibody. The docking site of these mAbs on TrkA and TrkC
overlaps, respectively, with the binding site of NGF and NT-3 on the
receptor IgG-C2 (D5) domains.
Direct FACScan Binding Assays
The FITC-peptidomimetics were tested by quantitative FACScan
for direct binding to NIH-TrkA cells, NIH-TrkC cells, NIH-p75 cells,
nnr5 cells (p75+++ Trk–), or wild-type NIH-3T3 control cells. Cells
were resuspended in binding buffer (PBS, 0.5% BSA, and 0.1%
NaN3) and 40 M of FITC peptidomimetics were added for 1 hr.
Cells were washed three times, acquired on a FACScan, and mean
channel fluorescence (MCF) of bell-shaped histograms was ana-
lyzed using the CellQuest program. MAbs 5C3 (anti-TrkA), 2B7
(anti-TrkC), and MC192 (anti-p75) were used as positive binding
controls, and mouse IgG-FITC was used as negative binding con-
trol. Nonbinding FITC-peptidomimetics were also made and used
as negative controls.
Competitive FACScan Binding Assays
Peptidomimetics were tested for their ability to block the binding of
mAbs 5C3 or 2B7 toward their respective receptors in quantitative
FACScan assays. Cells were resuspended in binding buffer (PBS,
0.5% BSA, and 0.1% NaN3) and saturating anti-TrkA mAb 5C3, or
anti-TrkC mAb 2B7 (w60 nM) or control nonbinding IgGs, were
added in the absence or presence of peptidomimetics (100 M) or
controls, as previously described [26]. Cells were then washed and
immunostained. Cells were acquired on a FACScan, and MCF of
bell-shaped histograms was analyzed using the CellQuest program.
pTyr Assays
Assays were performed, as previously described [46, 52], by West-
ern immunoblotting with antiphosphotyrosine (α-pTyr) antibody
4G10 (Upstate Biotechnology, Lake Placid, NY). After ligand treat-
ment (0.1 nM or 2 nM neurotrophins alone, or 50 M peptidomimet-
ics alone) at 37°C for 20 min, cells were solubilized and protein
concentrations were determined. Equal protein loading was con-
firmed by Coomassie blue staining of gels, and by stripping and
reblotting membranes with anti-pan Trk polyclonal antibody 203.
Quantification was done by densitometric analysis relative to opti-
mal (2 nM) neurotrophin.
Statistical Analyses
The data were analyzed with one-way ANOVA followed by t tests
with Bonferroni corrections; statistical significance is indicated in
some figures by an asterisk (*).
Supplemental Data
Supplemental Data, including structures and models and the elec-
trostatic maps of some compounds, are available at http://www.
chembiol.com/cgi/content/full/12/9/1015/DC1/.
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